Vadim Bichko

USPTO Granted Patents = 9 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 5.2

ph-index = 4

Forward Citations = 93(Granted Patents)

Company Filing History:

3 out of 100

Idenix Pharmaceuticals, Inc.

patents

3 out of 31

Universitá Degli Studi Di Cagliari

patents

2 out of 61

Janssen Sciences Ireland Unlimited Company

patents

4. 1 out of 111

Janssen Sciences Ireland Uc

patents

5. 3 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2021

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11084826 - RSV antiviral pyrazolo- and triazolo-pyrimidine compounds (2021-08-10),

2. 10611769 - RSV antiviral pyrazolo- and triazolo-pyrimidine compounds (2020-04-07),

3. 10525072 - 2'-branched nucleosides and flaviviridae mutation (2020-01-07),

4. 10208048 - RSV antiviral pyrazolo- and triazolo-pyrimidine compounds (2019-02-19),

5. 9428491 - Substituted azoles, antiviral active component, pharmaceutical composition, method for preparation and use thereof (2016-08-30),

6. 9381201 - Pharmaceutical composition and kit for treating bacterial infections (2016-07-05),

7. 8674085 - [object Object] (2014-03-18),

8. 8481587 - Substituted 2-(5-hydroxy-2-methyl-1H-indole-3-yl)acetic acids and ethers thereof and the use of same to treat viral diseases (2013-07-09),

9. 7824851 - 2'-branched nucleosides and Flaviviridae mutation (2010-11-02),

Title: The Innovative Contributions of Vadim Bichko

Introduction

Vadim Bichko is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of antiviral compounds. With a total of nine patents to his name, Bichko has made strides in developing novel pharmaceutical solutions aimed at combating viral infections.

Latest Patents

Among his latest innovations are the RSV antiviral pyrazolo- and triazolo-pyrimidine compounds. These compounds are designed to exhibit antiviral activity, specifically targeting the replication of the respiratory syncytial virus (RSV). The invention not only includes the compounds themselves but also pharmaceutical compositions that utilize these compounds for the treatment of RSV infections.

Career Highlights

Vadim Bichko has worked with notable organizations such as Idenix Pharmaceuticals, Inc. and Università Degli Studi Di Cagliari. His experience in these institutions has allowed him to refine his expertise in antiviral research and development.

Collaborations

Bichko has collaborated with esteemed colleagues, including Jean-Pierre Sommadossi and David N Standring, further enhancing the impact of his work in the field of antiviral therapies.

Conclusion

Vadim Bichko's innovative work in developing antiviral compounds showcases his dedication to advancing medical science. His contributions are vital in the ongoing fight against viral infections, particularly RSV.

This text is generated by artificial intelligence and may not be accurate.